257 related articles for article (PubMed ID: 17885735)
1. Topical henna for capecitabine induced hand-foot syndrome.
Yucel I; Guzin G
Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
[TBL] [Abstract][Full Text] [Related]
2. Topical henna ameliorated capecitabine-induced hand-foot syndrome.
Ilyas S; Wasif K; Saif MW
Cutan Ocul Toxicol; 2014 Sep; 33(3):253-5. PubMed ID: 24021017
[TBL] [Abstract][Full Text] [Related]
3. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
[TBL] [Abstract][Full Text] [Related]
4. [Management of capecitabine-induced hand-foot syndrome by local phytotherapy].
Kern E; Schmidinger M; Locker GJ; Kopp B
Wien Med Wochenschr; 2007; 157(13-14):337-42. PubMed ID: 17704983
[TBL] [Abstract][Full Text] [Related]
5. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Zhang RX; Wu XJ; Lu SX; Pan ZZ; Wan DS; Chen G
J Cancer Res Clin Oncol; 2011 Jun; 137(6):953-7. PubMed ID: 21113620
[TBL] [Abstract][Full Text] [Related]
6. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Son HS; Lee WY; Lee WS; Yun SH; Chun HK
Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
[TBL] [Abstract][Full Text] [Related]
7. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
Lee SD; Kim HJ; Hwang SJ; Kim YJ; Nam SH; Kim BS
Korean J Intern Med; 2007 Jun; 22(2):109-12. PubMed ID: 17616027
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
Do JE; Kim YC
Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and hand-foot syndrome.
Saif MW
Expert Opin Drug Saf; 2011 Mar; 10(2):159-69. PubMed ID: 21174613
[TBL] [Abstract][Full Text] [Related]
10. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Saif MW; Elfiky A; Diasio R
Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792
[TBL] [Abstract][Full Text] [Related]
11. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Wolf SL; Qin R; Menon SP; Rowland KM; Thomas S; Delaune R; Christian D; Pajon ER; Satele DV; Berenberg JL; Loprinzi CL;
J Clin Oncol; 2010 Dec; 28(35):5182-7. PubMed ID: 21060036
[TBL] [Abstract][Full Text] [Related]
12. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
Vickers MM; Easaw JC
J Gastrointest Cancer; 2008; 39(1-4):141-3. PubMed ID: 19440857
[TBL] [Abstract][Full Text] [Related]
13. [Hand-foot syndrome with capecitabine therapy].
Marini A; Hengge UR
Hautarzt; 2007 Jun; 58(6):532-6. PubMed ID: 16897045
[TBL] [Abstract][Full Text] [Related]
14. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
15. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
[TBL] [Abstract][Full Text] [Related]
16. High frequency of hand foot syndrome with capecitabine.
Kamil M; Haron M; Yosuff N; Khalid I; Azman N
J Coll Physicians Surg Pak; 2010 Jun; 20(6):421-2. PubMed ID: 20642979
[TBL] [Abstract][Full Text] [Related]
17. Acral and palmo-plantar hyperpigmentation in a patient with disseminated hepatocellular carcinoma.
Goyal R; Chalamalasetty SB; Madan K; Paul SB; Arora R; Safaya R; Acharya SK
Indian J Gastroenterol; 2007; 26(6):292-3. PubMed ID: 18431015
[TBL] [Abstract][Full Text] [Related]
18. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
19. [A case of severe hand-foot syndrome caused by capecitabine].
Shimomatsuya T; Mitsudou Y; Nakamura T; Yonezawa K; Shiraishi S; Fujino M; Maruhashi K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1139-41. PubMed ID: 17637558
[TBL] [Abstract][Full Text] [Related]
20. [Capecitabine-induced hyperpigmentation].
Vázquez-Bayo C; Rodríguez-Bujaldón AL; Jiménez-Puya R; Galán-Gutiérrez M; Moreno-Giménez JC
Actas Dermosifiliogr; 2007 Sep; 98(7):491-3. PubMed ID: 17669305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
